Last reviewed · How we verify
DPT-IPV-Hib (Combined Vaccine)
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.
This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | DPT-IPV-Hib (Combined Vaccine) |
|---|---|
| Also known as | BK1310 |
| Sponsor | Tanabe Pharma Corporation |
| Drug class | Pentavalent inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
DPT-IPV-Hib is a pentavalent inactivated vaccine that contains antigens from five pathogens. It works by presenting these antigens to the immune system, triggering both humoral (antibody-mediated) and cell-mediated immune responses that provide protection against these infectious diseases. The vaccine reduces the risk of infection by enabling the body to recognize and rapidly eliminate these pathogens upon exposure.
Approved indications
- Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
- Confirmatory Study of BK1310 in Healthy Infants (PHASE3)
- Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DPT-IPV-Hib (Combined Vaccine) CI brief — competitive landscape report
- DPT-IPV-Hib (Combined Vaccine) updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI